Nirav Shah to Lymphoma, Mantle-Cell
This is a "connection" page, showing publications Nirav Shah has written about Lymphoma, Mantle-Cell.
Connection Strength
2.771
-
Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma. J Clin Oncol. 2025 07 10; 43(20):2285-2295.
Score: 0.866
-
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. J Clin Oncol. 2023 08 20; 41(24):3988-3997.
Score: 0.761
-
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis. Curr Med Res Opin. 2025 Dec; 41(12):2323-2338.
Score: 0.230
-
Knowledge, skills, and confidence gaps impacting treatment decision making in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma: a quantitative survey study in France, Germany, and the United States. BMC Cancer. 2024 Aug 13; 24(1):1003.
Score: 0.207
-
Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2024 04; 24(4):254-259.
Score: 0.198
-
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK?inhibitor in BTK?inhibitor?naive mantle cell lymphoma. Future Oncol. 2022 Nov; 18(36):3961-3969.
Score: 0.184
-
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 03 06; 397(10277):892-901.
Score: 0.163
-
Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma? J Clin Oncol. 2021 02 10; 39(5):487-498.
Score: 0.162